Welcome to our dedicated page for Alaunos Therapeutics news (Ticker: TCRT), a resource for investors and traders seeking the latest updates and insights on Alaunos Therapeutics stock.
Alaunos Therapeutics, Inc. (TCRT) reports developments as an early-stage biotechnology company focused on orally administered small-molecule therapeutics for obesity and related metabolic disorders. Recent updates center on ALN1003, a non-hormonal, non-incretin oral candidate evaluated in preclinical diet-induced obesity models, including body-weight, liver and metabolic biomarker findings.
Company news also reflects Alaunos's transition from earlier TCR-T cell therapy programs for solid tumors, including the TCR-T Library trial, the Sleeping Beauty cell engineering platform and the hunTR discovery platform. Recurring corporate updates include operating results, research spending, capital-structure actions, Nasdaq listing compliance and governance changes.
Alaunos Therapeutics (TCRT) reports promising early data from its TCR-T Library Phase 1/2 trial, showcasing the first objective clinical response using non-viral Sleeping Beauty TCR-T cell therapy in solid tumors at the CICON conference. The company aims to treat more patients while expanding manufacturing capabilities to produce two products simultaneously. Financially, collaboration revenue surged 631% to $2.9 million, while net loss decreased to $8.9 million, improving cash burn by 36%. An IND amendment is expected to enhance speed and flexibility in manufacturing.
Alaunos Therapeutics (TCRT) will announce its financial results for Q3 2022 on November 14, 2022, prior to U.S. market opening. Following this, a conference call will be held at 8:30 a.m. ET to discuss the results and provide a corporate update. The company specializes in oncology-focused cell therapies, utilizing its proprietary Sleeping Beauty gene transfer technology to develop T-cell receptor therapies targeting oncogenic gene mutations like KRAS, TP53, and EGFR.
Alaunos Therapeutics, Inc. (Nasdaq: TCRT) has announced promising data from its human neoantigen T-cell receptor platform (hunTR) at the Society for Immunotherapy of Cancer's annual meeting. The proprietary hunTR platform enables rapid identification of neoantigen-reactive TCRs, enhancing Alaunos' TCR library. The study evaluated ~525,000 TCR+HLA+neoantigen combinations in patients with various cancers, with a median hit rate of 13% per patient. The company plans to expand the application of hunTR for additional mutations, aiming to advance personalized TCR-T therapies.
Alaunos Therapeutics has announced promising early clinical data from its TCR-T Library Phase 1/2 trial for treating solid tumors. The first patient experienced a confirmed partial response with a 51.2% tumor regression at three months post-infusion. The Sleeping Beauty TCR-T cell therapy demonstrated a manageable safety profile, with no dose-limiting toxicities observed. The data will be presented at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference on September 30, 2022. This therapy targets shared tumor-specific hotspot mutations, offering hope for patients with significant unmet medical needs.
HOUSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, announced participation in several investor conferences. Key events include:
- Wells Fargo Healthcare Conference on September 8, 2022, in Boston, MA (1x1 Meetings)
- Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, in New York, NY (1x1 Meetings)
- Cantor Oncology Conference on September 28, 2022, in New York, NY (Panel Presentation and 1x1 Meetings)
Alaunos Therapeutics has reported significant early findings from its TCR-T Library Phase 1/2 trial, marking a first objective clinical response in solid tumors via non-viral TCR-T cell therapy. The initial patient, diagnosed with non-small cell lung cancer and a KRAS mutation, exhibited a confirmed objective partial response. A second patient has completed the 28-day safety window. The results will be further detailed at the CRI-ENCI-AACR CICON conference on September 30, 2022, highlighting the potential of non-viral TCR-T therapies in treating solid tumors.
Alaunos Therapeutics (TCRT) announced its acceptance to present a talk at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference (CICON) in New York from September 28 – October 1, 2022.
The presentation titled "Objective clinical response by KRAS mutation-specific TCR-T cell therapy in previously treated advanced Non-small cell lung cancer" will be delivered by Dr. Marcelo V. Negrao on September 30, 2022, at 8:30 am ET.
Alaunos specializes in oncology-focused cell therapies and has a collaboration with the National Cancer Institute.
Alaunos Therapeutics (TCRT) announced their Phase 1/2 trial targeting KRAS, TP53, and EGFR mutations in solid tumors is actively enrolling patients. The company has appointed Abhishek Srivastava, Ph.D., as VP, Technical Operations, and extended its collaboration with the National Cancer Institute until 2025. Financially, Alaunos reported a 62% decrease in operating cash burn for Q2 2022 to $8.2 million, and a net loss of $9.9 million or $(0.05) per share. The company expects its cash runway to fund operations until Q2 2023.
Alaunos Therapeutics, Inc. (Nasdaq: TCRT) has appointed Dr. Abhishek Srivastava as Vice President of Technical Operations, effective immediately. Dr. Srivastava's role will focus on enhancing manufacturing operations, process optimization, and capacity expansion. With over 15 years of experience in cell therapy, he previously worked at Athenex and the University of Pittsburgh. This appointment comes as Alaunos advances its TCR T Library Phase 1/2 trial, leveraging its proprietary Sleeping Beauty technology. CEO Kevin Boyle expresses confidence in Dr. Srivastava’s ability to drive operational efficiency.
Alaunos Therapeutics, Inc. (Nasdaq: TCRT) has announced an extension of its Cooperative Research and Development Agreement with the National Cancer Institute (NCI) to January 2025. This agreement will utilize Alaunos’ proprietary non-viral Sleeping Beauty technology to develop personalized T-cell receptor (TCR) therapies. The partnership aims to create safe and effective TCR-T therapies for solid tumor cancer patients. Alaunos is confident that this collaboration will enhance their TCR-T platforms and increase the potential patient population for these therapies.